We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00342485
Recruitment Status : Completed
First Posted : June 21, 2006
Last Update Posted : July 2, 2017
Sponsor:
Information provided by:

Study Description
Brief Summary:
Peripheral blood mononuclear cells (PBMC) will be collected from healthy volunteers and patients who present with different diseases that involve or implicate the immune system dysregulation (HIV infection, autoimmune diseases and cancer). These PBMC will be studied in vitro for a number of functional parameters, including generating soluable factors that inhibit HIV infection, developing patterns of immune dysregulation, and inducing apoptotic T cell death. The purpose of such studies is to obtain insight into the mechanisms of natural resistance to viral infections, AIDS pathogenesis, and disease-induced immune dysregulation.

Condition or disease
Cell Function

Detailed Description:
Peripheral blood mononuclear cells (PBMC) will be collected from healthy volunteers and patients who present with different diseases that involve or implicate the immune system dysregulation (HIV infection, autoimmune diseases and cancer). These PBMC will be studied in vitro for a number of functional parameters, including generating soluable factors that inhibit HIV infection, developing patterns of immune dysregulation, and inducing apoptotic T cell death. The purpose of such studies is to obtain insight into the mechanisms of natural resistance to viral infections, AIDS pathogenesis, and disease-induced immune dysregulation.

Study Design

Study Type : Observational
Estimated Enrollment : 5000 participants
Official Title: In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients
Study Start Date : April 12, 1993
Estimated Study Completion Date : March 3, 2008
Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Greater than or equal to 18 years old.

Documented HIV infection by current DoD criteria (1 ELISA, 2 Confirmatory Western Blot) or by one of the following tests; DNA PCR, RNA PCR, p24 antigen test, viral culture assay.

CD4 lymphocyte cell count greater than 300 mm(3).

EXCLUSION CRITERIA:

Unable to provide informed consent.

Unable to meet the minimum (150 days) and maximum (395 days) research visit interval requirements.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00342485


Locations
United States, Texas
Willford Hall USAF Medical Center
San Antonio, Texas, United States, 78236
Sponsors and Collaborators
National Cancer Institute (NCI)
More Information

ClinicalTrials.gov Identifier: NCT00342485     History of Changes
Other Study ID Numbers: 999993010
OH93-NC-N010
First Posted: June 21, 2006    Key Record Dates
Last Update Posted: July 2, 2017
Last Verified: March 3, 2008

Keywords provided by National Institutes of Health Clinical Center (CC):
Cellular Immunity
HIV-infected
Immune Deficiency
Cancer
Transplantation